Fewer than 1% of docs sees bias in online CME, survey finds

Share this article:
A Medscape-sponsored survey of a million physicians participating in online CME found that fewer than 1% perceived bias, regardless of whether or not it was commercially supported.

Overall, 93.48% of the 1,064,642 respondents said didn't perceive bias in the CME they participated in, with another 5.89% expressing no opinion and only .63% saying they did sense bias. Of those participating in commercially-supported CME, .84% perceived bias, while .48% of those participating in non-commercially–supported CME sensed bias.

The survey asked participants to indicate whether they agreed or disagreed, strongly or not, with the statement “The activity was presented objectively and free of commercial bias.” The number of those strongly disagreeing was just .14% overall—.17% of those participating in commercially-supported CME and 11% of those taking part in non-commercially supported CME.

“If commercial support caused bias, our subgroup analysis of those who strongly disagreed would be expected to show a larger difference, not the smaller difference we observed,” wrote the study's authors.

The study appears in the September issue of The American Journal of Medicine. Its sponsor, WebMD's Medscape, is a leading provider of online CME, and data came from physicians taking part in online CME through the site. Of 1,621,647 physician participants, around 66% completed the survey
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.